<qa>  What is the dose-escalation study of the monotherapy of anti-LAG-3PART A: This is a dose-escalation study of the monotherapy of Anti-LAG-3 monoclonal antibody BMS-986016 and Anti-CD137 urelumab. Patients are assigned to 1 of 2 arms. 